Immune Netw.
2021 Feb;21(1):e8. 10.4110/in.2021.21.e8.
Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target
- Affiliations
-
- 1Department of Physiology, Daegu Catholic University School of Medicine, Daegu 42472, Korea
- 2Laboratory of Cancer Immunometabolism, National Cancer Institute, Frederick, MD 21702, USA
- 3Technical Assistance Center, Korea Food Research Institute, Wanju 55365, Korea
- 4Laboratory of Cytokine Immunology, Department of Biomedical Science and Technology, Konkuk University, Seoul 05029, Korea
- 5Department of Bioequivalence Division for Drug Evaluation, Ministry of Food and Drug Safety, Cheongju 28159, Korea
- 6Department of Medicine, Pusan Paik Hospital, College of Medicine, Inje University, Busan 47392, Korea
- 7College of Veterinary Medicine, Konkuk University, Seoul 05029, Korea
- 8Graduate School of International Agricultural Technology, Seoul National University, Pyeongchang 25354, Korea
- 9Veterinary Science Research Institute, Konkuk University, Seoul 05029, Korea
- KMID: 2513574
- DOI: http://doi.org/10.4110/in.2021.21.e8
Abstract
- The global crisis caused by the coronavirus disease 2019 (COVID-19) led to the most significant economic loss and human deaths after World War II. The pathogen causing this disease is a novel virus called the severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). As of December 2020, there have been 80.2 million confirmed patients, and the mortality rate is known as 2.16% globally. A strategy to protect a host from SARS-CoV-2 is by suppressing intracellular viral replication or preventing viral entry. We focused on the spike glycoprotein that is responsible for the entry of SARS-CoV-2 into the host cell. Recently, the US Food and Drug Administration/EU Medicines Agency authorized a vaccine and antibody to treat COVID-19 patients by emergency use approval in the absence of long-term clinical trials. Both commercial and academic efforts to develop preventive and therapeutic agents continue all over the world. In this review, we present a perspective on current reports about the spike glycoprotein of SARS-CoV-2 as a therapeutic target.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants
- Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
- Genetic diversity and evolutionary patterns of SARSCoV-2 among the Bhutanese population during the pandemic
- SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene
- Comparative genetic analyses of Korean bat coronaviruses with SARS-CoV and the newly emerged SARS-CoV-2
